The 2026 Amyloidosis Care Guide

This guide provides a detailed breakdown of the current treatment standards for the two most prevalent forms: AL (Light Chain) amyloidosis and ATTR (Transthyretin) amyloidosis. We will examine the specific protocols, novel agents, and diagnostic advancements that define the modern care pathway.

The Foundation: Understanding the Two Major Types

Precision therapy begins with accurate classification. The mechanism of disease differs significantly between AL and ATTR, dictating entirely different treatment strategies.

• AL Amyloidosis: A plasma cell disorder where misfolded immunoglobulin light chains form amyloid fibrils. The primary target is the clonal plasma cell.
• ATTR Amyloidosis: Caused by the misfolding of the transthyretin protein, produced primarily in the liver. The target is either stabilizing the protein or silencing its production.

AL Amyloidosis: The 2026 First-Line Standard

The treatment of newly diagnosed AL amyloidosis has been redefined. The era of melphalan-based regimens is firmly in the past. The current gold standard is a daratumumab-based quadruplet therapy.

The standard protocol in 2026 consists of:

• Daratumumab: A monoclonal antibody targeting CD38 on plasma cells. This is the backbone of modern therapy.
• Cyclophosphamide: An alkylating agent that damages the DNA of rapidly dividing plasma cells.
• Bortezomib: A proteasome inhibitor that disrupts protein processing, leading to plasma cell death.
• Dexamethasone: A corticosteroid that reduces inflammation and enhances the efficacy of the other agents.

This combination, often referred to as Dara-CyBorD, achieves deep hematologic responses rapidly. The goal is to suppress the production of the toxic light chains before irreversible organ damage occurs. For patients who are eligible, high-dose chemotherapy followed by autologous stem cell transplant remains a highly effective consolidation strategy, particularly for those achieving deep responses.

Next-Generation CAR-T for Relapsed AL Amyloidosis

For patients with relapsed or refractory AL amyloidosis, the therapeutic landscape has expanded dramatically. The most significant development is the emergence of next-generation CAR-T cell therapies.

The leading candidate in this space is NXC-201. This is a B-cell maturation antigen (BCMA)-targeted CAR-T therapy specifically designed for AL amyloidosis. Unlike earlier CAR-T products, NXC-201 is engineered for a more favorable safety profile, with a lower incidence of cytokine release syndrome and neurotoxicity, which are critical concerns for patients with cardiac involvement.

Clinical data from 2025 and 2026 demonstrate that NXC-201 can achieve high rates of complete hematologic response in heavily pretreated patients. This approach offers a potential curative pathway for those who have exhausted other options.

ATTR Amyloidosis: Stabilizers and Silencers

The treatment of ATTR amyloidosis is bifurcated into two primary strategies: stabilizing the native TTR protein or silencing its production at the genetic level. The choice depends on the patient’s genotype and disease stage.

TTR Stabilizers: Preventing Misfolding

The first generation of TTR stabilizers, like tafamidis, changed the natural history of ATTR cardiomyopathy. The 2026 standard has been elevated by the approval of acoramidis.

Acoramidis is a next-generation, high-affinity TTR stabilizer. Key advantages include:

• Superior stabilization: It binds more tightly to the TTR tetramer, preventing its dissociation into misfolded monomers.
• Near-complete stabilization: Clinical trials demonstrate it stabilizes >90% of TTR in the blood, compared to approximately 50% with tafamidis.
• Improved outcomes: Data from the ATTRibute-CM trial showed significant reductions in mortality and cardiovascular hospitalizations compared to placebo, with a trend toward superiority over tafamidis.

For patients with early-stage ATTR cardiomyopathy, acoramidis is now considered a preferred first-line stabilizer.

Gene-Silencing RNAi Agents: Stopping Production at the Source

For patients with ATTR polyneuropathy, or those with more aggressive disease, gene-silencing therapies offer a more potent approach. The leading agent in this class is vutrisiran, an RNA interference (RNAi) therapeutic.

Vutrisiran works by:

• Targeting mRNA: It directly targets and degrades the messenger RNA that codes for the TTR protein.
• Reducing production: This silences the gene in the liver, dramatically reducing the amount of TTR protein produced.
• Durable effect: Administered as a subcutaneous injection every three months, it provides sustained suppression of TTR levels.

The HELIOS-B trial demonstrated that vutrisiran not only halts neurologic progression but also shows significant benefit in cardiac endpoints, including reduced mortality and hospitalizations. This positions it as a dual-action therapy for patients with mixed phenotypes.

Early Detection: The Role of AI-Enhanced Echocardiography

The success of these precision therapies hinges on early diagnosis. Historically, amyloidosis was diagnosed late, often after significant organ damage had occurred. The integration of artificial intelligence into echocardiography is changing this paradigm.

AI-enhanced echocardiography can now detect subtle patterns of myocardial texture and strain that are invisible to the human eye. These algorithms are trained to identify the characteristic “granular sparkling” and reduced global longitudinal strain that suggest amyloid infiltration.

This technology is being deployed in routine echo labs as a screening tool. When the AI flags a study as suspicious for amyloidosis, it triggers a reflex workup that includes:

• Serum and urine immunofixation to rule out AL amyloidosis.
• Serum free light chain assay.
• Bone scintigraphy (PYP scan) to detect ATTR deposits.

This automated screening pathway is dramatically shortening the time to diagnosis, allowing patients to access disease-modifying therapies before their cardiac function deteriorates.

The Imperative of Multidisciplinary Care

Amyloidosis is a systemic disease. Even with the most effective plasma cell or TTR-directed therapy, patients require coordinated care to protect their organs from existing damage and ongoing deposition.

A modern multidisciplinary team includes:

• Cardiologist: Manages heart failure, arrhythmias, and monitors for amyloid cardiomyopathy progression. They oversee the use of beta-blockers, diuretics, and anticoagulation.
• Nephrologist: Prescribes renin-angiotensin system blockers to protect kidney function and manages volume status.
• Hematologist/Oncologist: Oversees the plasma cell-directed therapy for AL amyloidosis, including chemotherapy and CAR-T.
• Neurologist: Addresses autonomic dysfunction, peripheral neuropathy, and orthostatic hypotension.
• Nutritionist: Provides dietary guidance to manage nausea, early satiety, and protein loss.

The goal of this team is to preserve cardiac and renal function. Early intervention with diuretics, careful blood pressure management, and the avoidance of nephrotoxic agents are critical. In AL amyloidosis, the rapid reduction of light chains can lead to dramatic improvements in organ function, but this requires vigilant monitoring and supportive care.

The transition from symptom management to disease modification is now a reality. With daratumumab-based quadruplets for AL amyloidosis, next-generation CAR-T for relapsed disease, and potent TTR stabilizers and RNAi silencers for ATTR, the tools to alter the natural history of this disease are available. The key is early detection, accurate typing, and access to a specialized center that can deliver this comprehensive, precision-based care. This is the new standard for amyloidosis management in 2026.